The Microsatellite Instability (MSI) gold standard research tool is now an IVD, enabling better access for clinical diagnostic laboratories.
Tumor to Answer Overnight
The OncoMate™ MSI Dx System is a CE-marked IVD Assay that offers a complete workflow for MSI determination, from DNA extraction to data analysis, while leveraging the same informative MSI loci relied on by global clinical researchers for almost two decades. It is part of a broader workflow that includes DNA extraction from FFPE tissue samples, quantitation of DNA, amplification of specific microsatellite markers using multiplex PCR, fragment separation by capillary electrophoresis, and data analysis and interpretation.
The improved system is designed for use as a diagnostic with cancer patients to better inform potential immunotherapy decisions and assist in the diagnosis of hereditary cancer syndromes, like Lynch Syndrome.
A PCR-based fragment-sizing test, the OncoMate™ MSI Dx Analysis System offers an easy-to-use and standardized system with analytical sensitivity and unsurpassed specificity to detect alterations in repeat lengths in samples containing mismatch repair defects1,2.
1Bacher, J. et al. (2004) Dis. Markers 20, 237.
2Luchini C., et al. (2019) Annals of Oncology. 30, 1232.
Please contact our Product manager Christine Rindal Ibra for further information.